News


July 9th, 2018

Crohn’s disease clinical trial – Now enrolling

Qu Biologics is now recruiting Canadian residents to participate in the first stage of a Phase 2 clinical trial of QBECO SSI in the treatment of adults living with moderate to severe Crohn’s disease. The aim of this trial is to further establish the safety and efficacy of the investigational drug QBECO SSI for the […]

READ MORE >
May 16th, 2018

Leading-edge Scientists in Innate Immunity Join Qu Biologics’ Scientific Advisory Board

Vancouver, British Columbia – May 15th, 2018 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce the addition of four members to Qu’s Scientific Advisory Board (SAB), consisting of world leading experts in the fields of innate […]

READ MORE >
May 10th, 2018

Qu Biologics SSIs featured in Inside Tract magazine

Qu Biologics’ paradigm shifting approach to IBD is featured in the March April 2018 issue of the Gastrointestinal Society’s ‘Inside Tract’ magazine. Read the full article here

READ MORE >
April 20th, 2018

Qu Biologics begins Phase 2 Clinical Trial in Crohn’s disease

Qu Biologics Inc. (Qu), a Vancouver, Canada-based biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore innate immune function, is pleased to announce the receipt of a ‘No Objection Letter’ (NOL) from Health Canada and the initiation of their follow-on Phase 2 clinical trial to study QBECO SSI for […]

READ MORE >
April 4th, 2018

Julia Levy – a trailblazer for women in STEM

A woman of wisdom and influence and we’re proud to be associated – Julia Levy is a member of Qu Biologics Board of Directors and has blazed a trail for women in STEM. Read more about her journey here .  

READ MORE >
March 21st, 2018

Protected: IBD Advisory Panel meeting March 6 2018

There is no excerpt because this is a protected post.

READ MORE >
December 20th, 2017

Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress

Vancouver, British Columbia – Dec 19th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system is pleased to report that they will be presenting clinical outcome data from Qu’s recently completed Phase 2 study in ulcerative colitis at […]

READ MORE >
November 28th, 2017

Discovery of Innate Immune Mechanisms of a Novel Microbial-based Approach for the Treatment of Lung Cancer

Vancouver, British Columbia – November 28th, 2017 – Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has just published collaborative research with Dartmouth College detailing the mechanism of action and efficacy of Qu’s lung-targeted SSI, QBKPN, for the […]

READ MORE >
October 3rd, 2017

Response to Novel Immune Therapy for Ulcerative Colitis Associated with Genetic and Immune Biomarkers

Vancouver, British Columbia – October 3rd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has identified specific ulcerative colitis (UC) genetic markers that may predict response to QBECO SSI therapy and important immunological biomarkers that may be […]

READ MORE >
August 14th, 2017

Positive feedback from FDA reviewers in response to Pre-IND meeting package

Vancouver, British Columbia – August 14th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports positive and informative feedback from the US Food and Drug Administration (FDA) in response to Qu’s first Pre-IND meeting package submission. The […]

READ MORE >

Past events:


Past events: